Characterization of Effusion-Infiltrating T Cells: Benign versus Malignant Effusions

Clinical Cancer Research

Volumn 10, Issue 8, 2004, Pages 2600-2608

  Atanackovic, Djordje ^a   Block, Andreas ^a   De Weerth, Andreas ^a   Faltz, Christiane ^a   Hossfeld, Dieter Kurt ^a   Hegewisch Becker, Susanna ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA3BETA7 INTEGRIN; CD45RA ANTIGEN; CD56 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; L SELECTIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; ASCITES; BLOOD CELL; CALCULATION; CANCER PATIENT; CELL POLARITY; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EFFUSION; EXPERIMENT; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MEMORY CELL; NATURAL KILLER CELL; PHENOTYPE; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR LOCALIZATION;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELL ADHESION MOLECULES; FIBROSIS; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; NEOPLASMS; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CHEMOKINE; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 1942470399     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0239     Document Type: Article

References (69)

1. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
2. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
3. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
4. Salih HR, Nussler V. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance? Eur J Med Res 2001;6:323-32.
5. Guzman J, Hilgarth M, Bross KJ, et al. Lymphocyte subpopulations in malignant ascites of serous papillary ovarian adenocarcinoma. An immunocytochemical study. Acta Cytol 1988;32:811-5.
6. Robinson E, Segal R, Vesely Z, Mekori T. Lymphocyte subpopulations in peripheral blood and malignant effusions of cancer patients. Eur J Cancer Clin Oncol 1986;22:191-3.
7. Chen CK, Wu MY, Chao KH, Ho HN, Sheu BC, Huang SC. T lymphocytes and cytokine production in ascitic fluid of ovarian malignancies. J Formos Med Assoc 1999;98:24-30.
8. Guo YS, Xing ZL. A study of the cytotoxicity of malignant pleural effusion lymphocytes and LAK cells against autologous tumor cells. Chin Med J (Engl) 1994;107:903-5.
9. Oka M, Yoshino S, Hazama S, Shimoda K, Suzuki T. The characterization of peritoneal and pleural exudate cells from malignant effusions. Surg Today 1993;23:500-3.
10. Lockhart DC, Chan AK, Mak S, et al. Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery 2001;129:749-56.
11. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000;343:1020-34.
12. Jenkins MK, Khoruts A, Ingulli E, et al. In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol 2001;19:23-45.
13. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001;2:123-8.
14. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875-83.
15. Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 2002;195:135-41.
16. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32.
17. Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999;48:346-52.
18. Chen YM, Yang WK, Whang-Peng J, Kuo BI, Perng RP. Elevation of interleukin-10 levels in malignant pleural effusion. Chest 1996;110:433-6.
19. Radke J, Schmidt D, Bohme M, Morenz J, Weise W. Leukocyte and lymphocyte populations in peripheral blood and malignant ascites in patients with ovarian carcinoma. Geburtshilfe Frauenheilkd 1994;54:675-8.
20. Yamamoto J, Adachi Y, Onoue Y, et al. Differential expression of the chemokine receptors by the Th1- and Th2-type effector populations within circulating CD4+ T cells. J Leukoc Biol 2000;68:568-74.
21. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998;187:129-34.
22. D'Ambrosio D, Iellem A, Bonecchi R, et al. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol 1998;161:5111-5.
23. Wakugawa M, Nakamura K, Kakinuma T, Onai N, Matsushima K, Tamaki K. CC chemokine receptor 4 expression on peripheral blood CD4+ T cells reflects disease activity of atopic dermatitis. J Investig Dermatol 2001;117:188-96.
24. Panina-Bordignon P, Papi A, Mariani M, et al. The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Investig 2001;107:1357-64.
25. Oshikawa K, Yanagisawa K, Ohno S, Tominaga S, Sugiyama Y. Expression of ST2 in helper T lymphocytes of malignant pleural effusions. Am J Respir Crit Care Med 2002;165:1005-9.
26. Gotlieb WH, Abrams JS, Watson JM, Velu TJ, Berek JS, Martinez-Maza O. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 1992;4:385-90.
27. Shimokata K, Saka H, Murate T, Hasegawa Y, Hasegawa T. Cytokine content in pleural effusion. Comparison between tuberculous and carcinomatous pleurisy. Chest 1991;99:1103-7.
28. Chen YM, Yang WK, Whang-Peng J, Tsai CM, Perng RP. An analysis of cytokine status in the serum and effusions of patients with tuberculous and lung cancer. Lung Cancer 2001;31:25-30.
29. Strunk T, Bubel S, Mascher B, Schlenke P, Kirchner H, Wandinger KP. Increased numbers of CCR5+ interferon-gamma- and tumor necrosis factor- alpha-secreting T lymphocytes in multiple sclerosis patients. Ann Neurol 2000;47:269-73.
30. Fukada K, Sobao Y, Tomiyama H, Oka S, Takiguchi M. Functional expression of the chemokine receptor CCR5 on virus epitope-specific memory and effector CD8+ T cells. J Immunol 2002;168:2225-32.
31. Loetscher P, Uguccioni M, Bordoli L, et al. CCR5 is characteristic of Th1 lymphocytes. Nature 1998;391:344-5.
32. Aarvak T, Strand E, Teigland J, Miossec P, Natvig JB. Switch in chemokine receptor phenotype on memory T cells without a change in the cytokine phenotype. Scand J Immunol 2001;54:100-8.
33. Roman E, Miller E, Harmsen A, et al. CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J Exp Med 2002;196:957-68.
34. Kunkel EJ, Boisvert J, Murphy K, et al. Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am J Pathol 2002;160:347-55.
35. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Investig 1998;101:746-54.
36. Mack M, Bruhl H, Gruber R, et al. Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis. Arthritis Rheum 1999;42:981-8.
37. Bruhl H, Wagner K, Kellner H, Schattenkirchner M, Schlondorff D, Mack M. Surface expression of CC- and CXC-chemokine receptors on leucocyte subsets in inflammatory joint diseases. Clin Exp Immunol 2001;126:551-9.
38. Kabashima H, Yoneda M, Nagata K, Hirofuji T, Maeda K. The presence of chemokine (MCP-1, MIP-1alpha, MIP-1beta, IP-10, RANTES)- positive cells and chemokine receptor (CCR5, CXCR3)-positive cells in inflamed human gingival tissues. Cytokine 2002;20:70-7.
39. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12.
40. Hengel RL, Thaker V, Pavlick MV, et al. Cutting edge: L-selectin (CD62L) expression distinguishes small resting memory CD4+ T cells that preferentially respond to recall antigen. J Immunol 2003;170:28-32.
41. Chen G, Shankar P, Lange C, et al. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood 2001;98:156-64.
42. Tussey L, Speller S, Gallimore A, Vessey R. Functionally distinct CD8+ memory T cell subsets in persistent EBV infection are differentiated by migratory receptor expression. Eur J Immunol 2000;30:1823-9.
43. Hislop AD, Gudgeon NH, Callan MF, et al. EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol 2001;167:2019-29.
44. Urbani S, Boni C, Missale G, et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol 2002;76:12423-34.
45. Dunbar PR, Smith CL, Chao D, et al. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 2000;165:6644-52.
46. Valmori D, Scheibenbogen C, Dutoit V, et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 2002;62:1743-50.
47. Hammond KJ, Pelikan SB, Crowe NY, et al. NKT cells are phenotypically and functionally diverse. Eur J Immunol 1999;29:3768-81.
48. Lantz O, Bendelac A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 1994;180:1097-106.
49. Eberl G, Lees R, Smiley ST, Taniguchi M, Grusby MJ, MacDonald HR. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J Immunol 1999;162:6410-9.
50. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-6.
51. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986;164:814-25.
52. Ohkawa T, Seki S, Dobashi H, et al. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 2001;103:281-90.
53. Saeterdal I, thor Straten P, Myklebust JH, Kirkin AF, Gjertsen MK, Gaudernack G. Generation and characterization of gp100 peptide-specific NK-T cell clones. Int J Cancer 1998;75:794-803.
54. Baxevanis CN, Gritzapis AD, Tsitsilonis OE, Katsoulas HL, Papamichail M. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes. Int J Cancer 2002;98:864-72.
55. Vergelli M, Le H, van Noort JM, Dhib-Jalbut S, McFarland H, Martin R. A novel population of CD4+CD56+ myelin-reactive T cells lyses target cells expressing CD56/neural cell adhesion molecule. J Immunol 1996;157:679-88.
56. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 2000;164:1148-52.
57. Kambayashi T, Assarsson E, Michaelsson J, et al. Emergence of CD8+ T cells expressing NK cell receptors in influenza A virus-infected mice. J Immunol 2000;165:4964-9.
58. Slifka MK, Pagarigan RR, Whitton JL. NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells. J Immunol 2000;164:2009-15.
59. Takii Y, Hashimoto S, Iiai T, Watanabe H, Hatakeyama K, Abo T. Increase in the proportion of granulated CD56+ T cells in patients with malignancy. Clin Exp Immunol 1994;97:522-7.
60. Satoh M, Seki S, Hashimoto W, et al. Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol 1996;157:3886-92.
61. Ou D, Metzger DL, Wang X, Pozzilli P, Tingle AJ. Beta-cell antigen-specific CD56(+) NKT cells from type I diabetic patients: autoaggressive effector T cells damage human CD56(+) beta cells by HLA- restricted and non-HLA-restricted pathways. Hum Immunol 2002;63:256-70.
62. Barnaba V, Franco A, Paroli M, et al. Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with Hepatitis B virus. J Immunol 1994;152:3074-87.
63. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002;2:401-9.
64. Afford SC, Fisher NC, Neil DA, et al. Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis. J Pathol 1998;186:82-9.
65. Balkwill F. Chemokine biology in cancer. Semin Immunol 2003;15:49-55.
66. Sikora J, Zeromski J. Expression of TCR-zeta chain and apoptosis in subpopulations of tumor-associated lymphocytes (TALs) from malignant pleural effusions. Folia Histochem. Cytobiol 2002;40:347-51.
67. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72.
68. Deakin AM, Singh K, Crowe JS, et al. A lack of evidence for down-modulation of CD3 zeta expression in colorectal carcinoma and pregnancy using multiple detection methods. Clin Exp Immunol 1999;118:197-204.
69. Seitzer U, Kayser K, Hohn H, et al. Reduced T-cell receptor CD3zeta-chain protein and sustained CD3epsilon expression at the site of mycobacterial infection. Immunology 2001;104:269-77.